Altered plasma, urine, and tissue profiles of sulfatides and sphingomyelins in patients with renal cell carcinoma

Robert Jirásko, Jakub Idkowiak, Denise Wolrab, Aleš Kvasnička, David Friedecký, Krzysztof Polański, Hana Študentová, Vladimír Študent, Bohuslav Melichar, Michal HolčapekmedRxiv 2022 · DOI

TL;DR

Researchers have identified a specific "lipid signature" in the blood and urine of patients with renal cell carcinoma (RCC) that could lead to the first non-invasive diagnostic test for kidney cancer. By analyzing 674 samples using high-resolution mass spectrometry, the team found that concentrations of specific sulfatides and sphingomyelins shift predictably as the cancer progresses, offering a potential "liquid biopsy" with a classification accuracy (AUC) of over 0.97.

What Problem Does This Paper Address?

Renal cell carcinoma is the most common form of kidney cancer, but it is notoriously difficult to catch early. Unlike many other cancers, RCC has no established circulating biomarkers—there is no equivalent to the PSA test for prostate cancer or CA125 for ovarian cancer.

Currently, most kidney tumors are discovered incidentally during imaging for unrelated complaints. By the time symptoms appear, the cancer has often metastasized, significantly lowering survival rates. There is a dire "unmet medical need" for a non-invasive laboratory test that can distinguish between a malignant tumor and a benign kidney mass without requiring surgery or a painful biopsy.

Methods

The researchers employed MALDI-Orbitrap mass spectrometry, an ultra-high-resolution technique, to profile lipids in plasma, urine, and tissue samples.

  • Lipidomics Focus: They specifically targeted sulfatides (low-abundance acidic glycosphingolipids) and sphingomyelins (SM).
  • Analytical Validation: Because these lipids are often present in very low concentrations, the team used a "present/absent" approach for species below the limit of quantitation (LOQ).
  • Statistical Modeling: They used Principal Component Analysis (PCA) to visualize group separations and a logistic regression model with ridge penalty to build a classifier. This model incorporated 33 lipid concentrations, presence/absence data for 13 lipids, gender, and BMI.
  • Network Visualization: They used Cytoscape to map how lipid dysregulation flows through metabolic pathways across all three sample types (tissue, plasma, and urine).

Datasets

The study investigated a total of 674 samples from 369 subjects:

  • Cancer Group: 155 patients with various RCC subtypes (predominantly clear cell RCC, but also papillary and chromophobe subtypes).
  • Control Group: 214 healthy volunteers.
  • Sample Breakdown: 143 plasma, 100 urine, and 154 tissue samples (paired tumor and adjacent healthy tissue from the same patients).

Key Insights and Ideas

  • Systemic Metabolic Reprogramming: The most striking finding is that the lipid changes seen in the tumor tissue are mirrored in the blood and urine. This suggests that RCC isn't just a localized growth; it fundamentally alters the body's lipid metabolism.
  • The Hydroxylation Shift: The researchers observed a significant drop in hydroxylated sulfatides. This is likely linked to the downregulation of the enzyme FA2H (fatty acid 2-hydroxylase) in aggressive tumors, a phenomenon also seen in breast and colon cancers.
  • The Glutamine Connection: Elevated levels of lactosylsulfatides (SHex2Cer) were found in urine. The authors hypothesize this is a compensatory mechanism: cancer cells produce excess ammonium ions via glutamine metabolism, and negatively charged sulfatides may be secreted to balance that charge.
  • Stage-Dependency: The "lipid signal" gets stronger as the cancer advances. Patients with stage T3-T4 tumors showed much more pronounced dysregulation than those with T1-T2, suggesting these markers could also help monitor tumor progression.

Key Results

  • High Diagnostic Accuracy: The plasma-based classification model achieved an Area Under the Curve (AUC) of 0.973 for the testing set, with high sensitivity and specificity.
  • Specific Biomarkers:
    • Up-regulated: Lactosylsulfatides (SHex2Cer) in urine and tissue.
  • Down-regulated: Sphingomyelins with long saturated chains (e.g., SM 41:1) and hydroxylated monohexosyl sulfatides in plasma and urine.
  • Consistency: The circular dendrograms showed nearly perfect classification of controls versus cancer cases based solely on the concentrations of eight key lipid species.

Limitations and Future Work

While the results are promising, the authors acknowledge a few hurdles:

  • Age Imbalance: The control group and cancer group were not perfectly age-matched (cancer patients were generally older). While they built age-matched sub-models to verify their findings, a larger, more balanced cohort is needed.
  • Low Abundance: Some of the most telling sulfatides are present at the very edge of what current technology can detect. Improving the sensitivity of these "liquid biopsy" tests will be crucial for clinical adoption.
  • Clinical Validation: The study proves the potential for a test, but large-scale prospective clinical trials are required before a doctor can order a "kidney cancer lipid panel."

The researchers have already filed a pending patent for this diagnostic method, signaling a clear path toward moving this from the lab to the clinic.

Summary updated

Abstract

Abstract Renal cell carcinoma (RCC) represents the most common type of kidney cancer and, despite the progress of surgical and medical management, is associated with high mortality. In this study, we demonstrate that RCC-related processes change body fluids sphingolipid concentrations, which may be used to monitor tumor presence using non-invasive lipid-based blood and urine tests. We investigate 674 plasma, urine, and tissue samples from 369 RCC patients and controls. For the first time, we show the significant concentration changes of low abundant sulfatides in plasma and urine of RCC patients. Elevated concentrations of lactosylsulfatides, decreased concentrations of sphingomyelins with long saturated N-fatty acyls and sulfatides with hydroxylated fatty acyls are the crucial alternations in RCC. These changes are stage-dependent and are more emphasized in late-stage RCC. Similar trends in body fluids and tissues indicate that RCC widely influences lipid metabolism and highlights the potential of lipidomic profiling for cancer detection.
BibTeX
@misc{jirasko2022altered,
  author = {Robert Jirásko and Jakub Idkowiak and Denise Wolrab and Aleš Kvasnička and David Friedecký and Krzysztof Polański and Hana Študentová and Vladimír Študent and Bohuslav Melichar and Michal Holčapek},
  title = {{Altered plasma, urine, and tissue profiles of sulfatides and sphingomyelins in patients with renal cell carcinoma}},
  year = {2022},
  doi = {10.1101/2022.01.10.21268223},
  howpublished = {medRxiv},
}
Figure